Non-Alcoholic Fatty Liver Disease (NAFLD) is a common, yet complex, hepatic disorder that is emerging as a global health burden. It is a spectrum of diseases ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Understanding its causes, diagnostic methods, and modern therapeutic approaches is vital for effective patient management.
Although the pathogenesis of NAFLD is multifactorial, insulin resistance and metabolic syndrome are considered central to its development. Other factors include genetics, diet, gut microbiota, and sedentary lifestyle. NAFLD is often associated with obesity, type 2 diabetes, and dyslipidemia.
NAFLD is often silent, discovered incidentally during routine blood tests or imaging. However, a definitive diagnosis requires a liver biopsy, the gold standard for assessing liver histology. Non-invasive diagnostic strategies, such as ultrasound, elastography, and serum biomarkers, are also used to estimate liver fat content and fibrosis.
Current therapeutic strategies for NAFLD focus on lifestyle modifications, including diet and exercise. Pharmacological interventions are reserved for patients with NASH and significant fibrosis. These include insulin sensitizers, antioxidants, and lipid-lowering agents. Emerging therapies, such as FXR agonists and GLP-1R agonists, are showing promise in clinical trials.
NAFLD is a complex disease with multifactorial causes and a broad spectrum of clinical manifestations. Early identification and intervention are crucial to prevent progression to more severe liver disease. While lifestyle modification remains the cornerstone of management, advances in pharmacological therapies offer hope for more effective treatment options in the future. As our understanding of NAFLD continues to evolve, so too must our strategies for diagnosis and treatment.
1.
Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?
2.
The need for more Latinx participants in Alzheimer's trials is urgent.
3.
Admissions, medical colleges, fees, and eligibility requirements information for the DNB Post Diploma in Radiation Oncology.
4.
Study identifies new approach to protect the brain during radiation therapy
5.
Study Supports Lactated Ringer Solution for Fluid Resuscitation in SCD
1.
CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review
2.
Treating Oral Fibromas: Options and Guidelines for a Healthier Mouth
3.
The Genetics of Bernard Soulier Syndrome: What We Know so Far
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
Unlocking The Power Of Cangrelor To Treat Heart Disease
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
2.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
3.
Navigating the Complexities of Ph Negative ALL - Part XV
4.
Lung Cancer: Risk Factors and Prevention
5.
Thromboprophylaxis In Medical Settings
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation